Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0149514 (bronchitis)
 6,902 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The purpose of the present study was to compare the effects of two mucolytic drugs with different mechanism of action on mucociliary transport (MCT). N-acetylcysteine (NAC-600 mg/day) and ambroxol (AMB-90 mg/day) were administered according to a double-blind cross-over scheme to 12 heavy smokers suffering from hypersecretory bronchitis and homogeneous reduction of the MCT. Placebo of both treatments was administered during an interval of ten days between the administrations of NAC and AMB. The entire treatment period was 30 days. The data were analyzed according to ANOVA for the two-period cross-over clinical trial. The results indicate that: NAC and AMB, administered both before and after placebo, produce a significant increase in MCT, NAC showed a slightly greater efficacy than AMB, but the differences are not statistically significant. The overall efficacy of NAC and AMB is consistently greater than that of placebo. The sequence of administration of the drugs does not influence their effect.
 ...
PMID:Improvement of mucociliary transport in smokers by mucolytics. 386 8

The mucolytic activity of acetylcysteine (NAC) was evaluated in a double-blind, placebo controlled, clinical trial performed in three pneumology centres and involving a total of 215 patients with the following diagnoses: 84 acute bronchitis, 95 superinfections of chronic bronchitis, 36 complicated bronchitis in patients with severe chronic respiratory insufficiency. Treatment consisted of 1 sachet of 200 mg NAC t.i.d. for 10 days. Standard antibiotic therapy (amoxycillin 1.5 g/day) was concurrently administered for 7 days. Statistical analysis comparing sputum volume and viscosity, sedation of cough and improvement of PEFR in 108 NAC and in 107 placebo treated patients, showed that NAC was very significantly more effective than placebo. The effect of NAC was negligible in the 36 patients with complicated bronchitis, whereas it was evident and remarkable in patients with acute and chronic bronchitis.
 ...
PMID:[Multicenter, double-blind study of oral acetylcysteine vs. placebo]. 701 34

To help assess the causes and frequency of acute respiratory illnesses (ARI) during the first 18 months of life in Chile, a cohort of 437 children born in good health between May 1991 and April 1992 was followed at an urban health clinic in northern Santiago. Information was obtained from medical checkups performed at the clinic, from emergency health care services, from private physicians, and from interviews with each child's mother when the child was enrolled in the study and when it was 6, 12, and 18 months old. Followup was completed for 379 (87%) of the children. ARI accounted for 67% of all 3762 episodes of illness recorded for these children in the 18-month study period, 1384 (55%) of the ARI episodes affecting the upper respiratory tract and the remaining 1144 (45%) affecting the lower. The overall rate of ARI observed was 33 episodes per 100 child-months of observation. The incidences of upper, lower, and total ARI episodes decreased significantly in the third six months of life. A statistically significant association was found between upper ARI (> or = 2 episodes) and maternal smoking (> or = 5 cigarettes per day), but no significant associations were found with any of the other risk factors studied. However, lower ARI (> or 2 episodes) was significantly associated with maternal schooling (< 8 years), a family history of atopic allergy, and substandard housing conditions; and lower ARI (> or = 4 episodes) was significantly associated with these factors and also with the existence of one or more siblings, birth in a cold season, limited breast-feeding (< 4 months), and low socioeconomic status. Significant associations were found between obstructive bronchitis episodes and most of the risk factors studied (gender, siblings, season of birth, duration of breast-feeding, maternal schooling, smoking, use of polluting fuels in the home, and a family history of atopic allergy); similarly, significant associations were found between the occurrence of pneumonia and many risk factors (including siblings, season of birth, duration of breast-feeding, maternal schooling, smoking, and socioeconomic level). Overall, 42 of the study children were hospitalized during the study period for lower tract ARI, and two children died of pneumonia at home during their first 6 months of life. The rate of hospitalization fell significantly with increasing age.
Rev Panam Salud Publica 1997 Jan
PMID:Acute respiratory illnesses in the first 18 months of life. 912 8

A survey was conducted in Merida, Yucatan, between February and June 1994 in order to determine the prevalence of asthma and the frequency of a family history of the disease in school-age children. A random sample was taken of 505 children of both sexes between the ages of 6 and 12 who were enrolled in elementary schools in the urban area of Merida. Every child's father or mother was surveyed and asked if the child had had recurrent episodes of loud, difficult breathing with wheezing chest sounds, if he or she had had bronchitis, asthmatiform bronchitis, or asthma, and if the mother, father, or any of the siblings had ever suffered from asthma. A total of 61 children with asthma (cumulative prevalence, 12%) was found. Among these children a history of maternal or paternal asthma was more frequent (25 and 18%, respectively) than in other children (10 and 6%, respectively), the difference being statistically significant (P < 0.002) in both cases. Results show the high prevalence of asthma in Merida and suggest that heredity plays a role in the development of the disease.
Rev Panam Salud Publica 1997 Nov
PMID:[Prevalence of asthma in schoolchildren in Merida, Yucatan]. 944 Oct 19

This study was conducted in Mexico among residents of an area near a recycling plant for zinc and other metallic dusts to find out if these substances produce various adverse health effects in the population that may come in contact with them. The plant is in a municipality close to Monterrey, which is Mexico's third most populous and second most industrialized city. A cross-sectional comparative design was used for the research, which took place from September to November 1994. By means of quota sampling, houses were selected in two areas--one exposed, by virtue of its proximity to the plant, and the other unexposed, which served as a control--until the desired sample size was reached (621 individuals, an average of five per household). In each dwelling, a trained psychology student administered a questionnaire to one of the older family members to gather data on the presence of acute and chronic illnesses, problems during pregnancy, and congenital illnesses among the household members. In the exposed population, 127 questionnaires were completed, providing information on 596 persons; in the unexposed population, data on 743 persons were gathered via 147 questionnaires. The sex and age distributions were similar in the two populations, and the length of residence in their respective area was slightly longer among unexposed individuals. The most frequently reported health problems in the exposed population were irritation of the eyes and upper respiratory tract, allergies, sleep disturbances, bronchitis, fatigue, skin problems, ear infections, and anemia. The prevalence ratios for the exposed versus unexposed populations were significant with regard to skin eruptions and other skin diseases, fatigue, sleep disturbances, upper respiratory infections, ear infections, bronchitis, and allergies. Women from the two groups did not show significant differences in the prevalence of obstetric problems, miscarriages, or children born with congenital deformities or low birthweight. The sensitivity of the questionnaire used to detect health problems was poor, which could have resulted in an underestimation of some disorders. Nevertheless, various types of information bias were controlled, permitting the conclusion that the exposed population had a greater risk of suffering certain diseases and disorders than the unexposed population.
Rev Panam Salud Publica 1998 Jan
PMID:[Health status of the population in the vicinity of a waste recycling plant in Mexico]. 950 58

Erdosteine is a multifactorial drug currently used in COPD for its rheologic activity on bronchial secretions and its positive effects on bacterial adhesiveness. Erdosteine produces an active metabolite (Met 1) which was shown to produce antioxidant effects during the respiratory burst of human PMNs, due to the presence of an SH group. The substantial antitussive effects of erdosteine were first documented in clinical trials even though mucolytic agents are regarded as not consistently effective in ameliorating cough in patients with bronchitis, although they may be of benefit to this population in other ways. Actually, a mucolytic drug could exert antitussive effects if it also affects mucus consistency and enhances ciliary function. In the last decade, data from several studies on animal models pointed to the possible antitussive and anti-inflammatory properties of erdosteine and an indirect anti-inflammatory mechanism of action was suggested. Recently, data from some controlled versus placebo studies documented the antioxidant properties of erdosteine in humans and in current smokers with COPD. The mechanism of action was described as related to erdosteine's ability to inhibit some inflammatory mediators and some pro-inflammatory cytokines that are specifically involved in oxidative stress. As oxidative stress is also presumed to impair beta-adrenoceptor function and contribute to airway obstruction, specific controlled studies recently investigated the effect of antioxidant intervention on short-term airway response to salbutamol in nonreversible COPD, according to a double-blind design versus placebo and NAC. Only erdosteine consistently restored a significant short-term reversibility in COPD subjects, previously unresponsive to beta(2) adrenergics. This peculiar activity of erdosteine (to our knowledge never previously assessed) proved related to the ROS scavenging activity (which actually proved equal to that of N), and its significant inhibiting effect on lipoperoxidation (8-isoprostane) proved discriminant between treatments, with antioxidant and anti-inflammatory effects the main determinants of the erdosteine multifactorial properties. In addition, antitussive effects may be regarded as related to its anti-inflammatory properties via the improvement of mucociliary clearance and the reduction of chemokines from epithelial cells. Finally, a sort of "sensitization" of 2-adrenoceptors can also be speculated due to the same mechanisms of action; if confirmed by further controlled studies, this particular property would suggest a novel therapeutic role of erdosteine in COPD.
 ...
PMID:Erdosteine: antitussive and anti-inflammatory effects. 1818 58

Human health in the past and presently is influenced by the amounts and proportion of chemical elements to which humans have been exposed. Arsenic, as a therapeutic agent was known to ancient Greeks and Romans. Ehrlick introduced organic arsenicals as anti linetic agents but with advent of penicillin these have nearly become obsolete. Once considered toxic, harmful to humans, arsenic is now considered an essential ultra trace element at least in animals. Now the impact of arsenic on health is more from industrial and environmental than medicinal exposure. This article reviews human exposure to arsenic in non occupational population, mostly through drinking water which is a worldwide problem, more so in south East Asia. Sources of arsenic, normal and abnormal levels in blood and tissues levels, old and new methods of estimation of arsenic, mechanism of action of arsenic in experimental animal is briefly reviewed. Old described clinical manifestation of arsenic in humans is briefly reviewed and newly described clinical manifestations in human with special emphasis on atherosclerosis, liver and diabetes are discussed. Proposed biological mechanisms in experimental animals included up regulation of inflammatory signals like cytokines and TNF-alpha, oxidative stress, hypomethylation, decreased DNA repair and apoptosis, cell proliferation, angiogenesis, activation of several enzymes like methyl transferase which converts inorganic arsenic to MMA and DMA, and GSH in in-vivo and in-vitro in experimental rat liver slices. Experimentally NAC (N-Acetyl Cysteine) treatment attenuates oxidative stress in atherosclerosis apoptosis and liver injury. GSH probably plays an important role in deactivation of the intermediate products of arsenic metabolism and prevents peroxidation of membrane lipids. Chronic human exposure has been linked to several systems in the human body: dermal (exfoliative dermatitis, keratosis, vitiligo, skin cancer), peripheral neuropathy, encephalopathy, bronchitis, pulmonary fibrosis, hepatosplenomegaly resembling NCPF, portal hypertension, peripheral vascular disease and BFD, arteriosclerosis and cancers of lung, urinary bladder, other internal organs and diabetes. Experimental and epidemiological evidence support diabetes effect of high level arsenic exposure. Low and moderate exposure to arsenic in drinking water is widely prevalent and may play a role in diabetes prevalence and needs to be studied further. Role of arsenic in Indian arteriosclerosis, diabetes and liver diseases, (cirrhosis, NCPF), need to be studied further. Study of mechanisms and enzymes mentioned need to be studied in humans exposed to arsenic and other xenobiotics. Measuring arsenic exposure, metabolic and biologic effects by newly described and simpler urine proteomics may accelerate our understanding of arsenic on health consequences.
 ...
PMID:Arsenicosis: review of recent advances. 2175 19